Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Vepdegestrant (Veppanu) in India — Breast Cancer Protein Degrader Price & Access Guide
Approximate Price Comparison (per month supply)
India
$800 – $1,500
US
$12,000 – $18,000
UK
$8,000 – $12,000
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
On May 1, 2026, the FDA approved Veppanu (vepdegestrant) — the first protein degrader for breast cancer. This is not an incremental improvement. It is an entirely new class of drug that physically destroys mutated estrogen receptors instead of merely blocking them.
In the US, it will cost an estimated $12,000–$18,000 per month. Indian patients and medical tourists will likely access generics at $800–$1,500 per month once Indian manufacturers launch affordable versions.
Why Vepdegestrant Is a Breakthrough
Standard breast cancer hormone therapy works by blocking estrogen receptors. But cancer adapts. Approximately 30–40% of metastatic ER-positive breast cancers develop ESR1 mutations that make them resistant to tamoxifen, letrozole, and other standard hormone therapies.
Vepdegestrant takes a different approach. It is a heterobifunctional protein degrader — a molecule designed to tag the mutated ESR1 protein for destruction by the cell’s own waste-disposal system (the proteasome). The receptor is not blocked; it is eliminated.
This mechanism means:
- Works against cancers that have stopped responding to all standard hormone therapies
- Oral dosing (pill, not injection)
- First-in-class — no other approved drug uses this mechanism for breast cancer
India’s Oncology Drug Access Model
India has a proven track record of making expensive cancer drugs affordable:
| Cancer Drug | US Monthly Cost | India Monthly Cost | How India Got Access |
|---|---|---|---|
| Sorafenib (liver cancer) | $5,500 | $150 – $300 | Compulsory license (Natco, 2012) |
| Lenalidomide (myeloma) | $10,000+ | $200 – $400 | Voluntary license |
| Osimertinib (lung cancer) | $14,000 | $400 – $800 | Voluntary license |
| Palbociclib (breast cancer) | $12,000 | $300 – $600 | Generic competition |
| Vepdegestrant (projected) | $12,000 – $18,000 | $800 – $1,500 | Expected licensing |
The pattern is consistent: within 6-18 months of a major cancer drug’s global launch, Indian manufacturers — primarily Natco Pharma, Hetero Drugs, Cipla, and Dr. Reddy’s — bring affordable versions to market through licensing agreements or patent challenges.
Breast Cancer Treatment Costs: India vs US
For an international patient diagnosed with ESR1-mutated metastatic breast cancer, here is the full cost comparison:
| Treatment Component | India | US |
|---|---|---|
| Diagnostic workup (imaging, biopsy, genomic testing) | $500 – $1,200 | $5,000 – $15,000 |
| Monthly targeted therapy (vepdegestrant equivalent) | $800 – $1,500 | $12,000 – $18,000 |
| Oncologist consultations (per visit) | $30 – $80 | $300 – $500 |
| PET-CT scan (monitoring) | $150 – $300 | $3,000 – $6,000 |
| 6-month treatment total | $6,000 – $12,000 | $80,000 – $130,000 |
The savings are not marginal — they are life-altering for patients without comprehensive insurance coverage.
Top Indian Hospitals for Breast Cancer
Tata Memorial Hospital, Mumbai
- Volume: 70,000+ cancer patients annually
- Accreditation: WHO Collaborating Centre for Cancer
- International patients: Dedicated international wing
- Specialty: Comprehensive cancer center with clinical trials access
- Cost advantage: Government-subsidized, among the lowest cancer treatment costs in India
Rajiv Gandhi Cancer Institute, Delhi
- Volume: 30,000+ patients annually
- Accreditation: NABH, NABL
- Technology: Latest radiation, robotic surgery, molecular diagnostics
- International desk: Visa assistance, accommodation, interpreter services
HCG Cancer Centre, Bengaluru
- Network: 25+ cancer centers across India
- Technology: Proton therapy, CyberKnife, genomic profiling
- Clinical trials: Active participation in global oncology trials
- International patients: 15-20% of volume
Genomic Testing in India
ESR1 mutation testing — which determines whether vepdegestrant is appropriate — is available in India at dramatically lower cost:
| Test | US Cost | India Cost |
|---|---|---|
| Foundation One CDx (comprehensive genomic) | $5,000 – $7,000 | $800 – $1,500 |
| Liquid biopsy (ctDNA ESR1) | $3,000 – $5,000 | $400 – $800 |
| Single-gene ESR1 mutation test | $500 – $1,000 | $80 – $150 |
Indian diagnostic labs like Strand Life Sciences, MedGenome, and 4baseCare offer CLIA/CAP-equivalent genomic testing at a fraction of Western costs.
The Accelerated Approval Question
Vepdegestrant’s approval pathway matters for patients considering treatment:
- FDA approval status: Full approval based on phase 3 trial data
- Confirmatory data: Available and robust (unlike some accelerated approvals later withdrawn)
- Standard of care: Rapidly being adopted as first-line for ESR1-mutated metastatic breast cancer
This is not an accelerated approval at risk of withdrawal — it is a full approval with strong clinical evidence, making it a safe treatment choice for medical tourists planning care around this drug.
What Medical Tourists Should Do Now
- Get ESR1 mutation testing — either at home or upon arrival in India ($80–$150 for targeted test)
- Contact hospitals directly — reach out to the international patient departments at Tata Memorial, Rajiv Gandhi, or HCG for treatment cost estimates
- Ask about drug availability — confirm whether generic vepdegestrant is available at your target hospital, or whether the branded version can be imported under India’s compassionate access program
- Plan for ongoing treatment — if vepdegestrant is part of a long-term treatment plan, establish a telemedicine relationship with your Indian oncologist for prescription renewals and monitoring
Sources & References
- FDA Approval — Veppanu (vepdegestrant), May 1, 2026, for ER+/HER2- ESR1-mutated breast cancer
- AACR — FDA Approvals in Oncology, January-March 2026
- Targeted Oncology — FDA Oncology News April-May 2026
- Indian Council of Medical Research — Breast Cancer Statistics India, 2025
- Tata Memorial Hospital — International Patient Treatment Costs, 2026
- Natco Pharma — Oncology generics portfolio and licensing agreements
Frequently Asked Questions
What is Vepdegestrant (Veppanu) and why is it significant?
Vepdegestrant is the first heterobifunctional protein degrader approved for breast cancer. Unlike traditional drugs that block estrogen receptors, it physically destroys the mutated receptor protein (ESR1). It was FDA-approved on May 1, 2026 for ER-positive, HER2-negative breast cancer with ESR1 mutations — a cancer subtype that resists standard hormone therapy.
Is Vepdegestrant available in India?
As of May 2026, the branded version (Veppanu) is not yet launched in India. However, Indian oncology pharma companies like Natco Pharma and Hetero Drugs have a strong track record of launching affordable versions of cancer drugs through voluntary licensing agreements. Indian generic oncology drugs are typically available 6-18 months after US launch at 85-95% lower cost.
How much does breast cancer treatment cost in India vs the US?
Comprehensive breast cancer treatment in India costs $5,000–$15,000 depending on stage and treatment plan. The same treatment in the US costs $100,000–$300,000+. Individual targeted therapy drugs like Vepdegestrant cost $800–$1,500/month in India (generic, when available) vs $12,000–$18,000/month in the US.
What is an ESR1 mutation and why does it matter?
ESR1 mutations occur in the estrogen receptor gene, making breast cancer resistant to standard hormone therapies like tamoxifen and aromatase inhibitors. About 30-40% of metastatic ER-positive breast cancers develop ESR1 mutations during treatment. Before Vepdegestrant, these patients had limited treatment options. This drug represents a genuinely new therapeutic class.
Which Indian hospitals treat international breast cancer patients?
Top oncology hospitals for international patients include Tata Memorial Hospital (Mumbai), Rajiv Gandhi Cancer Institute (Delhi), HCG Cancer Centre (Bengaluru), Apollo Cancer Centre (Chennai), and Adyar Cancer Institute (Chennai). Tata Memorial Hospital alone treats 70,000+ cancer patients annually and is recognized as a WHO Collaborating Centre for Cancer.
How does Natco Pharma make cancer drugs affordable?
Natco Pharma has pioneered compulsory licensing and voluntary licensing agreements for cancer drugs in India. They were the first to obtain a compulsory license for a cancer drug (sorafenib) in 2012. Natco's oncology generics are priced 90-97% below originator prices and are exported to 40+ countries. This model makes breakthrough cancer drugs accessible in developing markets within months of global launch.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.